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Introduction 
Wearable devices are playing an increasing role in 
the management of health and disease. 
Consequently, adverse skin reactions to wearables 
are more common. For example, one study reported 
that 8 out of 10 pediatric diabetic patients wearing 
continuous glucose monitoring (CGM) devices 
experienced skin issues related to the device and 
another study cited cutaneous complications as the 
cause for 18% of patients who discontinued their use 
of CGM devices [1, 2]. Herein, we present a case of 
contact dermatitis to a CGM device and discuss the 
advantages of spray-on topical steroids in patients 
dealing with wearables. 
 
Case Synopsis 
A 40-year-old woman on insulin replacement 
therapy for diabetes presented to the dermatology 
clinic with a three-month history of a pruritic rash on 
her upper arms in the setting of wearing a new Flash 
Glucose Monitoring device, the FreeStyle® Libre 
(Abbott, Chicago, Il, US). The rash began on the right 
arm after two months of using the device, which is 
attached via a dermal adhesive and changed weekly. 
The eruption initially responded to triamcinolone 
0.5% cream. However, when the patient switched 
the device from the right arm to the left, a more 
severe reaction developed in the new area of device 
application. This failed to respond to 0.5% 
triamcinolone cream and a barrier solution 
recommended by the device manufacturer also 
failed to relieve the symptoms. 
On physical exam, a well-demarcated, round, 
erythematous, papulovesicular plaque was present 
on the left upper arm; the right arm exhibited a 
hyperpigmented patch (Figure 1). She was 
diagnosed with allergic contact dermatitis (ACD) to 
either the Freestyle® Libre wearable or adhesive on 
the device and prescribed clobetasol propionate 
0.05% spray for use prior to device attachment. The 
patient’s symptoms improved after two months of 
weekly application and hydrocortisone 1% spray was 
prescribed for maintenance. She remains symptom-
Abstract 
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dermatitis is challenging and new treatment options 
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In a 40-year-old woman with contact dermatitis to a 
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steroids are a good option for the treatment of 
dermatitis under wearable devices such as 
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free at the time of this report, five months after her 
initial presentation. 
 
Case Discussion 
This patient’s clinical history and examination 
findings are highly suggestive of ACD, a type IV 
delayed hypersensitivity reaction to an external 
allergen. Indeed, numerous cases of ACD caused by 
the FreeStyle® Libre CGM system have been reported 
and isobornyl acrylate, a component of the 
FreeStyle® Libre sensor, was identified to be the 
culprit allergen in 12 reported cases [3]. 
Although patch testing is the gold standard in the 
evaluation of ACD and avoidance of the offending 
agent is the definitive treatment, not all allergens can 
be avoided. Additionally, commercially available 
patch testing is only 70-80% sensitive, as these tests 
include only a limited selection of common allergens 
[4]. In the cases of medically-necessary adhesive 
devices, treatment through the skin symptoms may 
be preferred to stopping the offending agent; 
successful empiric initial management may offer 
relief to patients and help avoid unnecessary testing. 
In our case, the patient opted for a trial of empiric 
topical therapy prior to considering discontinuation 
of the device. 
Off-label use of nasal corticosteroid sprays has been 
recommended in the diabetes literature for 
cutaneous complications associated with diabetes 
devices, revealing a clinical unmet need for a topical 
corticosteroid formulations that are compatible with 
wearable devices [5]. Herein, we report the 
successful management of ACD to an adhesive CGM 
device with topical clobetasol 0.05% spray, a 
formulation of 0.05% clobetasol propionate in an 
alcohol-based vehicle. Once applied, it evaporates 
quickly and leaves almost no residue, thus making it 
an attractive option for use under occlusion [6]. 
These properties also make it an appealing and 
effective option for other similar uses, such as 
ostomy appliance-associated peristomal dermatitis. 
Taken together, topical corticosteroid sprays are a 
powerful addition to the arsenal of dermatologists, 
especially those managing patients who are 
struggling with unbearable wearables. 
Conclusion 
Spray formulations of topical steroids are a good 
option for the treatment of dermatitis under 
wearable devices such as continuous glucose 
monitors or ostomy appliance. 
 
Figure 1. A) Left arm. FreeStyle® Libre attached to the left upper 
arm. B) Left arm. Round, erythematous, papulovesicular plaque 
surrounded by scattered erythematous papules on the left upper 
arm. C) Right arm. Round, hyperpigmented patch surrounded by 
excoriated, hyperpigmented papules on the right upper arm. 
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